The effectiveness of atypical antipsychotic medications in depressive disorders

Current Psychiatry Reports

Volumn 6, Issue 6, 2004, Pages 422-424

  IsHak, Waguih William ^b   Rapaport, Mark H ^a   Gotto, Jennifer G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MILNACIPRAN; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE MODEL; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; NONHUMAN; NORADRENERGIC SYSTEM; RELAPSE; REMISSION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME; PATHOPHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 15944429684     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0005-0     Document Type: Review

References (20)

1. American Psychiatric Association: Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2004. Washington, DC: APPI; 2004:461-463.
2. Alexopoulos GS, Streim J, Carpenter D, Docherty JP: Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004, 65(suppl 2):5-99.
3. Voruganti L, Cortese L, Owyeumi L, et al.: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002, 57:201-208.
4. Keck Jr PE, Strakowski SM, McElroy SL: The efficacy of atypical antipsychotic medications in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J ClinPsychiatry 2000, 61(suppl 3):4-9.
5. McIntyre R, Katzman M: The role of atypical antipsychotic medications in bipolar depression and anxiety disorders. Bipolar Disord 2003, 5(suppl 2):20-35.
6. Sharpley AL, Bhagwagar ZH, Sepehr WW, et al.: Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 2003, 64:192-196.
7. Hirose S, Ashby Jr CR: An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002, 63:733-736.
8. Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999, 69:256-259.
9. Tani K, Takei N, Kawai M, et al.: Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsychopharmacol 2004, 7:55-58.
10. Shelton RC, Tollefson GD, Tohen M, et al.: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158:131-134.
11. Corya SA, Andersen SW, Detke HG, et al: Long term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open label study. J Clin Psychiatry 2003, 64:1349-1356.
12. Parker G: Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. Int Clin Psychopharmacol 2002, 17:87-89.
13. Sokolski KN, Denson TF: Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:863-866.
14. Adson DE, Kushner MG, Eiben KM, Schulz SC: Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depression Anxiety 2004, 19:121-126.
15. Gunasekara NS, Spencer CM, Keating GM: Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs 2002, 16:645-652.
16. Papakostas GI, Petersen TJ, Nierenberg AA, et al.: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65:217-221.
17. Lieberman JA: Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
18. Sharma V: Atypical antipsychotic medications and suicide in mood and anxiety disorders. Bipolar Disorders 2003, 5(suppl 2):48-52.
19. Alphs LD, Campbell BJ: Clozapine: Treatment of mood symptoms. Psychiatr Ann 2002, 32:722-729.
20. Hirschfeld RM: The efficacy of atypical antipsychotic medications in bipolar disorders. J Clin Psychiatry 2003, 64(suppl 8):15-21.